Memantine also can inhibit NMDARs after associating with a second site accessible in the absence of agonist, a process termed second site inhibition (SSI) that is not observed with ketamine. Here we investigated the effects of 1 mM Mg 2þ on recovery from inhibition by memantine and ketamine, and on memantine SSI, of the four main diheteromeric NMDAR subtypes. We found that: recovery from memantine inhibition depended strongly on the concentration of memantine used to inhibit the NMDAR response; Mg 2þ accelerated recovery from memantine and ketamine inhibition through distinct mechanisms and in an NMDAR subtypedependent manner; and Mg 2þ occupation of the deep site disrupted memantine SSI in a subtypedependent manner. Our results support the hypothesis that memantine associates with, but does not inhibit at the second site. After associating with the second site, memantine can either slowly dissociate directly to the extracellular solution, or transit to the deep site, resulting in typical channel block. Memantine's relatively slow dissociation from the second site underlies the dependence of NMDAR recovery from inhibition on both memantine concentration and on Mg 2þ .
a b s t r a c t
Memantine and ketamine are NMDA receptor (NMDAR) open channel blockers that are thought to act via similar mechanisms at NMDARs, but exhibit divergent clinical effects. Both drugs act by entering open NMDARs and binding at a site deep within the ion channel (the deep site) at which the endogenous NMDAR channel blocker Mg 2þ also binds. Under physiological conditions, Mg 2þ increases the IC 50 s of memantine and ketamine through competition for binding at the deep site. Memantine also can inhibit NMDARs after associating with a second site accessible in the absence of agonist, a process termed second site inhibition (SSI) that is not observed with ketamine. Here we investigated the effects of 1 mM Mg 2þ on recovery from inhibition by memantine and ketamine, and on memantine SSI, of the four main diheteromeric NMDAR subtypes. We found that: recovery from memantine inhibition depended strongly on the concentration of memantine used to inhibit the NMDAR response; Mg 2þ accelerated recovery from memantine and ketamine inhibition through distinct mechanisms and in an NMDAR subtypedependent manner; and Mg 2þ occupation of the deep site disrupted memantine SSI in a subtypedependent manner. Our results support the hypothesis that memantine associates with, but does not inhibit at the second site. After associating with the second site, memantine can either slowly dissociate directly to the extracellular solution, or transit to the deep site, resulting in typical channel block. Memantine's relatively slow dissociation from the second site underlies the dependence of NMDAR recovery from inhibition on both memantine concentration and on Mg 2þ .
Introduction
NMDA receptors (NMDARs) are a class of ionotropic glutamate receptors found at most fast excitatory synapses in vertebrate nervous systems (Iacobucci and Popescu, 2017a) . NMDARs are implicated in many disorders of the central nervous system, driving sustained interest in therapeutically targeting NMDARs to treat disease (Paoletti et al., 2013; Parsons and Raymond, 2014) . The clinical utility of two NMDAR channel blockers, memantine and ketamine, lend hope that continued development of drugs that modify NMDAR function may lead to new therapies for numerous disorders (Abdallah et al., 2015; Johnson et al., 2015; Parsons and Raymond, 2014) . Despite sharing similar mechanisms of action at NMDARs, memantine and ketamine have strikingly divergent clinical profiles (Abdallah et al., 2015; Johnson et al., 2015; Parsons et al., 2007) . Memantine is approved for the treatment of moderate to severe Alzheimer's disease and is clinically well tolerated (Lipton, 2006; Parsons et al., 2007; Parsons and Raymond, 2014) . In contrast, ketamine was initially approved as an anesthetic and has shown efficacy as a rapid antidepressant and in treatment of pain, but causes psychotomimetic side effects at therapeutic doses (Abdallah et al., 2015; Krystal et al., 2003; Persson, 2013) . A more thorough understanding of the differential mechanisms of memantine and ketamine action may aid development of novel therapeutics for treatment of nervous system disorders.
NMDARs are glutamate-and glycine-gated ion channels that exhibit unique biophysical properties including highly voltage-dependent channel block by physiological concentrations (~1 mM) of Mg 2þ (Mayer et al., 1984; Nowak et al., 1984) . Mg 2þ inhibition and other NMDAR biophysical properties vary substantially depending on the identity of the GluN2 subunits that constitute the receptor Paoletti et al., 2013) . NMDARs are heterotetramers typically composed of two GluN1 and two GluN2 subunits. One gene encodes the GluN1 subunit, whereas four genes encode four GluN2 subunits: GluN2A, GluN2B, GluN2C, and GluN2D (Iacobucci and Popescu, 2017a; Paoletti et al., 2013) . The specific combination of subunits that make up an intact receptor defines the NMDAR subtype, of which there are many. For example, a GluN1/2A receptor subtype refers to an NMDAR that contains two GluN1 and two GluN2A subunits. Here we focus on the four GluN1/ 2 diheteromeric NMDAR subtypes: GluN1/2A, GluN1/2B, GluN1/2C, and GluN1/2D receptors. Due to NMDAR subtype-dependent structural differences, Mg 2þ inhibition varies among NMDAR subtypes (Kuner and Schoepfer, 1996; Monyer et al., 1994; Siegler Retchless et al., 2012) . Mg 2þ exhibits similar inhibition of GluN1/ 2A and GluN1/2B receptors, and similar inhibition of GluN1/2C and GluN1/2D receptors, but Mg 2þ inhibits GluN1/2A and GluN1/2B receptors more potently than GluN1/2C and GluN1/2D receptors. Inhibition of all four GluN1/2 diheteromeric NMDAR subtypes by Mg 2þ , memantine, and ketamine can be reduced or eliminated by mutation of critical asparagine residues at the N-site in the M2 pore-lining region of NMDARs (Burnashev et al., 1992; Kashiwagi et al., 2002; Kuner and Schoepfer, 1996; Yamakura et al., 1993) . These asparagine residues therefore are thought to play an essential role in forming the site, or overlapping sites, where channel blockers bind, referred to here as the deep site. Because Mg 2þ competes with organic NMDAR channel blockers for binding at the deep site, Mg 2þ increases the IC 50 of organic channel blockers, including memantine and ketamine Lerma et al., 1991; Nikolaev et al., 2012; Otton et al., 2011) . At a concentration of 1 mM, Mg 2þ increases the memantine and ketamine IC 50 s for inhibition of GluN1/2A and GluN1/2B receptors at À66 mV~17-fold. However, 1 mM Mg 2þ increases the memantine and ketamine IC 50 s for inhibition of GluN1/2C and GluN1/2D receptors only~3-fold because of the lower Mg 2þ potency at these NMDAR subtypes . Therefore, in physiological Mg 2þ , memantine preferentially inhibits GluN1/2C
and GluN1/2D receptors, an effect proposed to impact strongly the clinical effects of memantine (Povysheva and Johnson, 2016) . However, NMDAR subtype discrimination by memantine decreases with depolarization ), inhibition of GluN1/2A receptors increases with increasing intracellular Ca 2þ concentration (Glasgow et al., 2017) , and low-dose memantine inhibition of GluN2A-and GluN2B-containing receptors reduces firing frequency in vivo (Szegedi et al., 2010) . Thus, inhibition by memantine of all GluN1/2 receptor subtypes is likely to play important roles in the clinical actions of memantine. Although the effects of Mg 2þ on memantine and ketamine IC 50 s are consistent with a competitive binding model, other data suggest a more complex interaction between Mg 2þ and organic NMDAR channel blockers (Nikolaev et al., 2012 . As a result, our ability to predict how organic NMDAR channel blockers act at NMDARs under physiological conditions, which may depend importantly on the effects of a physiological Mg 2þ concentration (Gideons et al., 2014) , is limited.
There are several differences between memantine and ketamine that may underlie their distinct clinical actions including binding to non-NMDAR targets (e.g., Lu et al., 2010; Maskell et al., 2003) and differences in pharmacokinetics (e.g., Hesselink et al., 1999; Lord et al., 2013 , but see Kotermanski et al., 2013) . In addition to differences in non-NMDAR targets and pharmacokinetics, there is a prominent distinction between memantine and ketamine action at NMDARs: the ability of memantine (Blanpied et al., 1997; Chen and Lipton, 2005; , but not ketamine , to inhibit NMDARs via second site inhibition (SSI), a type of inhibition observed following drug association with a second site accessible in the absence of agonist. Although the clinical implications of memantine action at a second site are not clear, SSI has been suggested to contribute to the clinical safety of memantine (Chen and Lipton, 2005; Parsons et al., 2007) . However, the effect of Mg 2þ on memantine action at the second site has not been explored. Therefore, we investigated the effects of 1 mM Mg 2þ both on the time course of recovery from inhibition by memantine and ketamine, and on memantine SSI.
Materials and methods

Cell culture and transfection
Experiments were performed on the tsA201 cell line (The European Collection of Authenticated Cell Cultures), which is a variant of the HEK 293 cell line. tsA201 cells were maintained as previously described (Glasgow and Johnson, 2014) in DMEM supplemented with 10% fetal bovine serum and 1% GlutaMAX (Thermo Fisher Scientific), either with or without 100 IU/ml of penicillin and 100 mg/ml streptomycin (Corning). 1 Â 10 5 cells/dish were plated on 15 mm glass coverslips treated with poly D-lysine (0.1 mg/ml) and rat-tail collagen (0.1 mg/ml, BD Biosciences) in 35 mm petri dishes. 12e24 h after plating, the cells were transiently cotransfected using FuGENE 6 Transfection Reagent (Promega) with mammalian expression plasmids that contained cDNAs encoding enhanced green fluorescent protein (EGFP in pRK7) for identification of transfected cells, the rat GluN1-1a subunit (hereafter GluN1; GenBank X63255 in pcDNA3.1), and either the rat GluN2A subunit (GenBank M91561 in pcDNA1), the rat GluN2B subunit (GenBank M91562 in pcDNA1), the rat GluN2C subunit (GenBank M91563 in pcDNA1), or the rat GluN2D subunit (GenBank L31612 in pcDM8).
For some experiments we used cells transfected with GluN1 and an EGFP:pIRES:GluN2A construct, which was a kind gift from Dr. Kasper Hansen (Hansen, unpublished). Briefly, EGFP was inserted in pIRES (Clontech) under transcriptional control of the CMV promoter, and the open reading frame of rat GluN2A (GenBank D13211) was inserted after the IRES sequence. cDNA ratios used were 1:1:1 (EGFP, GluN1, and GluN2A); 1:1 (GluN1 and EGFP:pIR-ES:GluN2A); or 1:1:3 (EGFP, GluN1, and GluN2B, C, or D). cDNA for the GluN1(N616R) mutant subunit (residue numbering starting from initiating methionine) was a kind gift from Dr. Pierre Paoletti and was transfected at the same ratio as wild-type GluN1. Immediately after transfection, the culture medium was supplemented with the competitive NMDAR antagonists D,L-2-amino-5-phosphonopentanoate (200 mM) and 7-chlorokynurenic acid (200 mM) to prevent NMDAR-mediated cell death.
Solutions
The extracellular bath solution contained (in mM): 140 NaCl, 2.8 KCl, 1 CaCl 2 , 10 HEPES, 0.01 EDTA, and 0.1 glycine, balanced to pH 7.2 ± 0.05 with NaOH and osmolality raised to 290 ± 10 mOsm with sucrose. L-glutamate, MgCl 2 , memantine, and (R,S)-ketamine (hereafter, ketamine) were added to the extracellular solution as indicated from frozen concentrated stock solutions on the same day as experiments. The intracellular pipette solution contained (in mM): 130 CsCl, 10 HEPES, 10 BAPTA, and 4 MgATP balanced to pH 7.2 ± 0.05 with CsOH; solution osmolality was 280 ± 10 mOsm. Frozen aliquots of pipette solution were thawed and kept on ice until loaded into pipettes immediately before starting an experiment.
Electrophysiology
Whole-cell voltage-clamp recordings were performed on transfected tsA201 cells 12e72 h after transfection. Pipettes were pulled from borosilicate capillary tubing (Sutter Instruments) on a Sutter Instruments-Flaming Brown P-97 microelectrode puller and fire polished to a resistance of 2e5 МU. Whole-cell recordings were made from cells expressing EGFP identified by epifluorescence illumination on an inverted Zeiss Axiovert microscope. Cells were held at a membrane potential (V m ) of À65 mV, unless otherwise indicated, corrected for an empirically determined liquid junction potential between the extracellular and intracellular solution of À6 mV. Whole-cell currents were amplified using an Axopatch 200B patch-clamp amplifier (Molecular Devices), low-pass filtered at 5 kHz and sampled at 20 kHz in pClamp10 (Molecular Devices). Series resistance was compensated 85e90% with the prediction and correction circuitry in all experiments.
Solutions were delivered to cells through a ten-barrel fast perfusion system described previously (Glasgow et al., 2017) . We determined the time course of solution exchange around whole cells by recording current relaxations following movements between two adjacent barrels. The initial barrel contained normal extracellular solution and 1 mM glutamate, and the barrel to which test movements were made contained extracellular solution with 50% NaCl and 1 mM glutamate. Solution exchange around a whole cell had a 10e90% rise time of 150 ± 35 ms (mean ± SD) and was well fit by a single exponential with a time constant of 27.4 ± 6.6 ms (mean ± SD).
Accurate measurement of the time course of recovery from inhibition by an inhibitory drug requires a rapid decrease of drug concentration to well below its IC 50 . Effective drug washout can require multiple solution exchange time constants, especially with higher drug concentrations. Therefore, some of our measurements of the t fast of recovery from drug inhibition may have been limited by the speed of solution exchange. For example, at a starting concentration of 100 mM drug, after 150 ms (~5 time constants) the drug concentration would be~0.4 mM, which is still close to the IC 50 for memantine or ketamine ).
However, measurements of the t slow of recovery from drug inhibition should have been unaffected by limitations of solution exchange around a whole cell, even at the highest drug concentrations used.
Analysis
All data were analyzed with Clampfit 10.3 or 10.7 (Molecular Devices), or GraphPad Prism 7. Time course of recovery from inhibition by memantine or ketamine was determined from drug concentration-inhibition relation experiments. Briefly, glutamate was applied for 10e20 s until current reached steady state, then glutamate with 1, 10, 100, or 1000 mM memantine or ketamine was applied for 10e40 s until a new steady-state current level was reached. Glutamate in the absence of drug was then reapplied for 20e60 s to allow recovery from inhibition. The time necessary to reach a steady level of inhibition and to allow recovery from inhibition depended on the NMDAR subtype, as expected for channel blockers. Experiments in which NMDAR-mediated current during recovery from inhibition did not reach at least 90% of steady-state NMDAR-mediated current preceding drug application were excluded from analysis.
Time course of recovery from memantine and ketamine inhibition was measured by performing least-squares fits of single or double exponential functions to current traces using Clampfit 10.3 or 10.7. The number of components used in exponential fits was determined by visual examination, using the fewest components required to obtain a satisfactory fit. For comparison with the time constant (t) of single exponential fits, a weighted time constant (t w ) was calculated from the results of double exponential fits using SSI was measured using the following SSI protocol: (a) 1 mM glutamate was applied for 20 s, and control current before SSI (I control1 ) was measured (see below); (b) normal extracellular solution was applied for at least 9 s to allow full deactivation of receptors; (c) memantine in the absence of glutamate was applied for 30 s; (d) memantine was washed away by a 1 s application of normal extracellular solution; (e) 1 mM glutamate was reapplied for 20 s for GluN1/2A receptors and for 40 s for GluN1/2C receptors, and current during SSI (I SSI ) was measured; (f) normal extracellular solution was applied for at least 40 s; (g) 1 mM glutamate was reapplied for 20 s and control current after SSI (I control2 ) was measured. We chose to use a 1 s wash (>30-fold longer than the t of solution exchange) in step (d) to ensure complete removal of memantine from the extracellular solution while still maintaining substantial SSI (t of recovery from SSI is~2 s ).
The minimum fractional response after SSI (minimum I SSI /I control ) was measured by comparing I SSI to the average of I control1 and I control2 with a point-by-point ratio (Iacobucci and Popescu, 2017b) of I SSI /I control , where I control ¼ ((I control1 þ I control2 )/2) (see Fig. 5 ). Each of the currents was aligned to the time of glutamate application. We measured the minimum I SSI /I control as the mean of I SSI / I control over a 200 ms window centered on the minimum ratio value. The time constant of recovery from SSI (t recovery SSI) was measured by fitting a single exponential function to recovery of I SSI /I control (see Fig. 5 To determine whether addition of 1 mM extracellular Mg 2þ affects the time course of recovery from inhibition by memantine and ketamine, we first measured recovery from inhibition by memantine and ketamine in 0 Mg 2þ . We used 1, 10 and 100 mM memantine or ketamine to assess the time course of recovery from inhibition for each drug with the four GluN1/2 diheteromeric NMDAR subtypes: GluN1/2A, GluN1/2B, GluN1/2C, and GluN1/2D
receptors. Drug concentrations below 1 mM were not used because the small amount of inhibition prevented reliable measurements of recovery from inhibition. We assessed the time course of recovery from inhibition by comparing time constants of single (t) or double exponential (t w ) fits to current relaxations following rapid removal of drug in the continuous presence of agonists (see Materials and Methods). NMDARs were activated using 1 mM glutamate (applied at times indicated in figures) and 100 mM glycine (present in all extracellular solutions) to assure that all measurements were performed at saturating agonist concentrations (Traynelis et al., 2010) . The time course of recovery from memantine and ketamine inhibition exhibited powerful NMDAR subtype dependence. At each memantine and ketamine concentration, recovery from inhibition was fastest for GluN1/2A receptors, slower for GluN1/2B receptors, and slowest for GluN1/2C and GluN1/2D receptors ( Fig. 1B; Fig. 2B ; Tables 1 and 2 ). These results are consistent with a defining characteristic of open channel blockers: recovery from inhibition occurs only when the channel is open, and thus speed of recovery from inhibition correlates with receptor maximal open probability (P open ), which is highest for GluN1/2A, lower for GluN1/ 2B, and lowest for GluN1/2C and GluN1/2D receptors (Chen et al., 1999; Dravid et al., 2008; Erreger et al., 2005; Wyllie et al., 1998) .
We found in 0 Mg 2þ that the time course of recovery from memantine inhibition of each NMDAR subtype depended strongly on the concentration of memantine used to inhibit the response ( Fig. 1B ; Fig. 3D ; Table 1 ). Consistent with previous studies (Gilling et al., 2007; , recovery from inhibition was slower at higher memantine concentrations, although we observed greater dependence of recovery time course on memantine concentration than reported previously (see Discussion). The t w of recovery from inhibition with 100 mM memantine was 11.7-fold slower than with 1 mM memantine for GluN1/2A receptors (p ¼ 0.0002), 5.1-fold slower for GluN1/2B receptors (p ¼ <0.0001), 2.5-fold slower for GluN1/2C receptors (p ¼ 0.04), and 1.9-fold slower for GluN1/2D receptors (p ¼ 0.002; Fig. 1B ; Fig. 3D ; Table 1 ). In sharp contrast, we found that the time course of recovery from ketamine inhibition was weakly concentration-dependent in GluN1/2A receptors, and was not concentration-dependent in GluN1/2B, GluN1/2C, and GluN1/ 2D receptors ( Fig. 2B ; Fig. 4D ; Table 2 ). These data are consistent with previous reports of no concentration dependence of recovery from ketamine inhibition (MacDonald et al., 1991; Parsons et al., 1995 Parsons et al., , 1996 . The t w of recovery from inhibition with 100 mM ketamine was only 1.6-fold slower than with 1 mM ketamine for GluN1/2A receptors (p ¼ 0.01), which is~10-fold less slowing than Representative current traces illustrating ketamine concentration independence of recovery from ketamine inhibition for GluN1/2A e GluN1/ 2D receptors (Ba-Bd). Current traces show recovery from ketamine (blue bars) inhibition in the continuous presence of glutamate (black bars) for GluN1/2A receptors (Ba; from cell used for panel A), or from similar experiments for GluN1/2B e GluN1/2D receptors (Bb-Bd). Pairs of traces at the indicated ketamine concentrations are aligned at the time of ketamine removal, and scaled to the change in current amplitude during recovery from inhibition. Results of exponential fits to recovery from ketamine inhibition data are shown in Fig. 4D and Table 2 . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
for memantine for GluN1/2A receptors. This small but significant increase could have resulted from limitations in the speed of solution exchange on washout of high drug concentrations (see Materials and Methods). Importantly, both t slow and A slow Table 1 Components of the time course of recovery from memantine inhibition.
Values represent means ± SEM, n ¼ 5e7 cells per condition. Statistical significance of comparisons of t w values is displayed in Fig. 3D . . For GluN1/ 2C and GluN1/2D receptors in 1 mM Mg 2þ , we used four memantine and ketamine concentrations (1, 10, 100, and 1000 mM).
We found that in 1 mM Mg 2þ
, the time course of recovery from memantine inhibition from each NMDAR subtype also exhibited strong concentration dependence ( Fig. 3AeB,D ; Table 1 ). The t w of recovery with 1000 mM memantine was 9.5-fold slower than with 10 mM memantine for GluN1/2A receptors (p ¼ 0.0005), 5.8-fold slower for GluN1/2B receptors (p ¼ 0.002), 2.4-fold slower for GluN1/2C receptors (p ¼ 0.02), and 2-fold slower for GluN1/2D receptors (p ¼ 0.002; Fig. 3B,D ; Table 1 ). Recovery from ketamine inhibition was only weakly concentration-dependent in 1 mM Mg 2þ for GluN1/2A receptors, and was concentration independent for GluN1/2B, GluN1/2C, and GluN1/2D receptors ( Fig. 4AeB,D ; Table 2 ), similar to results in 0 Mg 2þ . Interestingly, we found that recovery of GluN1/2A receptors from inhibition by 100 mM memantine and of GluN1/2B receptors from inhibition by 10 and 100 mM memantine was significantly faster in 1 mM than in 0 Mg 2þ ( Fig. 3CeD ; Table 1 ). Note that for GluN1/2A and GluN1/2B receptors, 10 and 100 mM memantine are the highest concentrations at which recovery from inhibition in 0 and 1 mM Mg 2þ can be compared. In contrast, recovery from memantine inhibition of GluN1/2C or GluN1/2D receptors was not faster in 1 mM than in 0 Mg 2þ , and recovery of GluN1/2C receptors from inhibition by 1 mM memantine was slower in 1 mM than in 0 Mg 2þ ( Fig. 3CeD ; Table 1 ). Recovery of GluN1/2A receptors from inhibition by 10 mM ketamine was significantly slower in 1 mM than in 0 Mg 2þ ; recovery of GluN1/2B receptors from inhibition by 10 and 100 mM ketamine was significantly faster in 1 mM than in 0 Mg 2þ ; Mg 2þ had no effect on recovery from ketamine inhibition of GluN1/2C and GluN1/2D receptors ( Fig. 4CeD ; Table 2 ). The mechanism responsible for the small and variable slowing by Mg 2þ of recovery from memantine and ketamine inhibition is not clear; one possibility is screening of surface potential Nowak, 1988, but see Zarei and Dani, 1994) by Mg 2þ (Isaev et al., 2012 (Paoletti et al., 1995) and therefore should accelerate the time course of recovery from inhibition; potentiation of GluN1/2B receptors by Mg 2þ should also contribute to acceleration of the time course of recovery of GluN1/2B receptors from memantine inhibition.
Recovery from memantine SSI represents the slow component of recovery from memantine inhibition
Dependence of recovery from inhibition on memantine concentration is surprising if inhibition results from interaction of memantine with a single site. Concentration dependence of the time course of drug binding (and thus of inhibition) is expected, since binding occurs in the presence of a varying drug concentration. In contrast, concentration dependence of drug unbinding kinetics (and thus recovery from inhibition) is atypical, since unbinding always occurs at the same drug concentration ([drug] ¼ 0). Memantine concentration dependence of recovery from inhibition was proposed to reflect an ability of memantine to interact with two sites . However, the hypothesis that the site responsible for SSI (Blanpied et al., 1997; Chen and Lipton, 2005; ) is involved in the memantine concentration dependence of recovery from inhibition has not been tested. Consistent with this hypothesis, memantine, but not ketamine, exhibits both SSI ) and strong concentration dependence of recovery from inhibition (data presented above). Previous data suggest that, paradoxically, the memantine SSI IC 50 (~100 mM; Blanpied et al., 1997; ) is much higher than the memantine IC 50 for deep site inhibition (~1 mM; Glasgow et al., 2017) , but the time course of recovery from memantine SSI is relatively slow (Blanpied et al., 1997; . High IC 50 with slow recovery from inhibition is atypical because the speed of recovery of channel blockers generally increases as IC 50 increases . Thus, we hypothesized that the slow component of recovery from memantine inhibition, which increases in relative amplitude as memantine concentration increased, reflects recovery from memantine SSI. We next evaluated this hypothesis by examining the time course of recovery from memantine SSI in 0 Mg 2þ .
To assess memantine SSI, we used the SSI protocol described in Materials and Methods (see Fig. 5AeB ), which is similar to protocols used previously (Blanpied et al., 1997; . We used 100 mM memantine, which is near the previously estimated memantine SSI IC 50 (80e180 mM (Blanpied et shown in Fig. 3 , the effects of Mg 2þ on the time course of recovery from memantine inhibition are similar for GluN1/2A and GluN1/2B receptors, and are similar for GluN1/2C and GluN1/2D receptors. We therefore examined NMDAR subtype dependence of memantine SSI here by comparing data from GluN1/2A and GluN1/2C receptors, first in 0 Mg 2þ and later in 1 mM Mg 2þ . We focus exclusively on memantine SSI because we previously showed that ketamine does not exhibit significant SSI ). In 0 Mg 2þ , we observed that 100 mM memantine induced robust SSI of GluN1/2C as well as GluN1/2A receptors. The minimum I SSI / I control was slightly but significantly (p ¼ 0.035) lower for GluN1/2C (0.44 ± 0.03) than for GluN1/2A receptors (0.56 ± 0.03; Fig. 5AeB ; Fig. 6G ). These data suggest that the potency of memantine SSI for GluN1/2A and GluN1/2C receptors is similar. The SSI protocol involves a 30-s application of 100 mM memantine in control solution.
If our control solution contained a low concentration of contaminating glutamate, it may have permitted some memantine block to occur through open channels that we then misinterpreted as SSI. To control for this possibility, we repeated the SSI protocol while coapplying with memantine a competitive antagonist of glutamate binding (50 mM APV; Fig. 5CeD ). If a portion of the SSI we observed were due to memantine block of open NMDARs activated by contaminating glutamate, then coapplication of APV with memantine should increase the minimum I SSI /I control (bring the minimum I SSI /I control closer to 1, indicating less SSI). In contrast, when 50 mM APV was coapplied with 100 mM memantine, the minimum I SSI /I control was not increased, but slightly decreased for GluN1/2A receptors ( Fig. 5C ; minimum I SSI /I control : memantine, 0.56 ± 0.03; memantine þ APV, 0.42 ± 0.02, p ¼ 0.01) and was indistinguishable for GluN1/2C receptors ( Fig. 5D ; minimum I SSI /I control : memantine, 0.44 ± 0.03; memantine þ APV, 0.49 ± 0.03; p ¼ 0.84). To determine whether complete unbinding of APV occurred during the 1 s wash following application of memantine and APV, we repeated the SSI protocol using a 30 s application of 50 mM APV alone (with no memantine). We observed no "SSI" using only 50 mM APV with GluN1/2A or GluN1/2C receptors (data not shown; minimum I SSI / I control : GluN1/2A, 1.02 ± 0.02; GluN1/2C, 1.04 ± 0.01). Thus, glutamate contamination of control solutions did not result in artefactual inhibition by memantine of open NMDARs. We conclude that SSI reflects a mechanism of memantine access to both GluN1/2A and GluN1/2C NMDARs distinct from conventional open channel block, consistent with previous reports using neuronal NMDARs (Blanpied et al., 1997; . The remaining SSI experiments were conducted without coapplication of APV. Despite similar memantine SSI potency for GluN1/2A and GluN1/2C receptors, the time course of recovery from SSI appeared to be faster for GluN1/2A than for GluN1/2C receptors. To quantify the time course of recovery from SSI we measured the t recovery SSI (see Materials and Methods). We found that the time course of recovery from SSI was~3-fold faster for GluN1/2A than for GluN1/ 2C receptors (t recovery SSI: GluN1/2A, 5.51 ± 0.33 s; GluN1/2C, 17.1 ± 1.4 s; p < 0.0001). It is unclear why the time course of recovery from SSI is faster for GluN1/2A than for GluN1/2C receptors. Possible explanations include dependence on NMDAR properties that differ between GluN1/2A and GluN1/2C receptors, such as maximal P open , gating kinetics or desensitization (Glasgow et al., 2015; Paoletti et al., 2013) . As we hypothesized, the time course of recovery from SSI for GluN1/2A and GluN1/2C receptors is strikingly similar to the t slow of recovery from inhibition by 100 mM memantine in 0 Mg 2þ , which also exhibits~3-fold difference between GluN1/2A and GluN1/2C receptors (Table 1) . Indeed, the t recovery SSI was indistinguishable from the t slow of recovery from inhibition by 100 mM memantine for GluN1/2A and GluN1/2C receptors (Table 1 ; t recovery SSI vs. t slow of recovery from inhibition by 100 mM memantine: GluN1/2A, p ¼ 0.99; GluN1/2C, p ¼ 0.31).
These data strongly support our hypothesis that the slow component of recovery from memantine inhibition, which becomes more prominent as memantine concentration increases ( Fig. 1 
SSI requires memantine transit from the second site to the deep site
If memantine SSI requires transit of memantine from the second site to the deep site, then elimination of deep site binding by memantine should also eliminate memantine SSI. To test this prediction, we determined whether mutating the GluN1 N-site asparagine residue, which is critical to deep site binding by channel blockers, affects memantine SSI. We mutated the GluN1 N-site to an arginine (GluN1(N616R)), which greatly increases the memantine IC 50 (Chen and Lipton, 2005; Kashiwagi et al., 2002) .
We measured the minimum I SSI /I control for GluN1(N616R)/2A and GluN1(N616R)/2C receptors (Fig. 7AeB,D) using the SSI protocol as shown in Fig. 5AeB . Strikingly, we found that SSI was completely abolished in GluN1(N616R)/2A and in GluN1(N616R)/ 2C receptors. We also performed the SSI protocol with 500 mM memantine, a concentration that nearly saturates SSI in native NMDARs and in wild-type GluN1/2A receptors (Blanpied et al., 1997; . Even with 500 mM memantine, SSI was absent in GluN1(N616R)/2A receptors (Fig. 7CeD) . These data are consistent with the hypothesis that memantine association with the second site does not inhibit NMDARs, and that SSI requires transit of memantine from the second to the deep site. Inhibition would occur exclusively after memantine transits to the deep site, explaining why SSI was abolished by mutation of the deep site (Fig. 7) , and was reduced by Mg 2þ occupation of the deep site (Fig. 6) . We cannot rule out that the possibility that the GluN1(N616R) deep site mutation also may indirectly affect association of memantine with the second site. To further test our hypothesis that memantine SSI requires transit from the second site to the deep site in wild-type NMDARs, we next took advantage of the strong voltage dependence of memantine inhibition at the deep site (Blanpied et al., 1997; Bresink et al., 1996; Chen and Lipton, 1997; Frankiewicz et al., 1996) . If SSI occurs via memantine transit from the second site to the deep site, then SSI should significantly decrease at depolarized voltage. SSI previously was found to be voltage-dependent, although less voltage-dependent than inhibition at the deep site (Blanpied et al., 1997) . However, the previous experiments were interpreted assuming that occupation of the second site was sufficient to inhibit NMDAR responses. If SSI requires memantine transit from the second site to the deep site, then voltage dependence of SSI could result from the voltage dependence of dissociation from the deep site. In this case, occupation of the second site could exhibit negligible or no voltage dependence. We therefore determined whether occupation of the second site differed at À65 mV and 35 mV by comparing in 0 Mg 2þ the results of three SSI protocols: (a) a protocol performed entirely at À65 mV (Fig. 8AeB) ; (b) a protocol performed entirely at 35 mV (Fig. 8CeD) ;
(c) a protocol in which 100 mM memantine was applied at 35 mV, but the rest of the protocol was performed at À65 mV (V m Jump; Fig. 8EeF ). Experiments were performed using both GluN1/2A and GluN1/2C receptors; results described below apply to both NMDAR subtypes. We found that when the entire SSI protocol was performed at 35 mV (protocol (b); Fig. 8CeD,G) , the minimum I SSI /I control was significantly greater (reflecting weaker inhibition) than when the entire protocol was performed at À65 mV (protocol (a); Fig. 8AeB,G) , confirming that memantine SSI is voltage-dependent. However, when memantine was applied at 35 mV and the minimum I SSI /I control measured at À65 mV (protocol (c); Fig. 8EeG ), the minimum I SSI /I control was indistinguishable from the minimum I SSI / I control at À65 mV, but was significantly less (reflecting greater inhibition) than the minimum I SSI /I control at 35 mV. These results show that memantine association with the second site is voltageindependent, but that subsequent SSI depends on voltage. Protocol (c) (Fig. 8EeF) demonstrates that when applied at 35 mV, memantine associated with the second site; protocol (b) (Fig. 8CeD) demonstrates that memantine occupation of the second site did not result in NMDAR response inhibition. Thus, SSI is voltage-dependent, but only insofar as inhibition requires occupation of the deep site via memantine transit from the second site to the deep site.
Discussion
This study was initiated to investigate the effects of Mg 2þ on the time course of recovery from inhibition by memantine and ketamine of the four main diheteromeric NMDAR subtypes, GluN1/2A e GluN1/2D receptors. Our results provide several new insights into mechanisms of memantine and ketamine inhibition in the absence and presence of Mg 2þ . We found that in 0 Mg 2þ , the time course of recovery from memantine inhibition is~2-to 10-fold slower following inhibition by 100 mM than following inhibition by 1 mM memantine ( Fig. 1; Fig. 3D ). The time course of recovery from ketamine inhibition, in contrast, demonstrated minimal dependence on ketamine concentration ( Fig. 2; Fig. 4D ). These data are consistent with the hypotheses that memantine inhibits via the deep site and via SSI, whereas ketamine inhibits via the deep site, but not via SSI (Blanpied et al., 1997; Chen and Lipton, 2005; Johnson et al., 2015; Parsons et al., 2007; . The concentration dependence of recovery from memantine inhibition and the minimal concentration dependence of recovery from ketamine inhibition were maintained in 1 mM Mg 2þ ( Fig. 3AeB,D; Fig. 4AeB,D) .
We demonstrated that 1 mM Mg 2þ accelerates recovery from memantine and ketamine inhibition in an NMDAR subtypedependent manner ( Fig. 3CeD; Fig. 4CeD ). We inferred that Mg 2þ accelerates recovery from memantine inhibition of GluN1/2A
and GluN1/2B receptors by reducing SSI, a form of inhibition from which recovery is surprisingly slow (Fig. 5AeB) . In addition, it is likely that Mg 2þ accelerates recovery from both memantine and ketamine inhibition of GluN1/2B receptors as a result of a Mg 2þ -induced increase in P open (Paoletti et al., 1995) . We showed that Mg 2þ reduces memantine SSI, but not as a result of Mg 2þ competition for association with the second site (Fig. 6) . To test the alternative hypothesis that Mg 2þ reduces memantine SSI by competing for binding to the deep site, we mutated the GluN1 asparagine essential to formation of the deep site. We found that mutation of the deep site also eliminated SSI (Fig. 7) . Examination of the voltage dependence of SSI and of memantine association with the second site further supported the conclusion that memantine occupation of the second site does not result in NMDAR inhibition (Fig. 8) ; inhibition only occurs after memantine transits from the second site to the deep site.
Determinants of the time course of recovery of NMDAR inhibition by memantine
Our finding that the time course of recovery from memantine inhibition depends strongly on the memantine concentration used to induce inhibition is inconsistent with previous studies that reported little or no concentration dependence (Frankiewicz et al., 1996; Gilling et al., 2007 Gilling et al., , 2009 Parsons et al., 1993 Parsons et al., , 1995 . However, several previous studies did report an increase in the amplitude of the slow component of recovery from memantine inhibition with increasing drug concentration . We also saw an increase in the amplitude of the slow component of recovery from memantine inhibition. However, overall, we saw a greater dependence of recovery from inhibition on memantine concentration than has been reported previously. We believe our examination of single NMDAR subtypes and several aspects of our experimental conditions explain most of the differences between our results and those of previous studies.
We were able to study single NMDAR subtypes because our experiments were conducted in a heterologous expression system as opposed to neurons (Blanpied et al., 1997; Frankiewicz et al., 1996; Gilling et al., 2007; Parsons et al., 1993 Parsons et al., , 1995 , which contain a heterogeneous population of NMDAR subtypes, including triheteromeric NMDARs (Al-Hallaq et al., 2007; Glasgow et al., 2015; Luo et al., 1997; Paoletti et al., 2013) . As the time course of recovery from inhibition differed greatly across NMDAR subtypes ( Fig. 1B;  Fig. 3D; Table 1 ), the presence of multiple NMDAR subtypes could alter interpretation of measurements obtained from neurons. Nevertheless, we see clear concentration dependence of the time course of recovery from memantine inhibition across NMDAR subtypes, which is consistent with previous observations in neurons .
In addition, several of our experimental conditions may have facilitated observation of concentration-dependent recovery from memantine inhibition by permitting us to observe fast recovery from deep site inhibition by memantine. Concentration dependence of the time course of recovery from memantine inhibition can be detected only if recovery from deep site inhibition is much faster than recovery from SSI. The rapid component of recovery from inhibition was much faster than the slow component under our experimental conditions because of our use of: (a) solutions that promoted high NMDAR P open , (b) a perfusion system that permitted rapid elimination of memantine from the extracellular solution, and (c) use of tsA201 cells, which are more compact than neurons, permitting nearly simultaneous solution exchange around the entire cell, and recording of currents that are not slowed by neurite cable properties. Our use of solutions that increased NMDAR P open was important because recovery from memantine inhibition at the deep site can occur only when the channel is open; increasing P open therefore accelerates recovery from memantine inhibition at the deep site. NMDAR P open was increased by our use of a saturating concentration of the full agonist glutamate, rather than a low or intermediate concentration of the partial agonist NMDA or aspartate (Traynelis et al., 2010) used in most other studies. To prevent NMDAR current rundown, thereby also maintaining a relatively high P open , we included ATP in the intracellular solution (Tong and Jahr, 1994) ; ATP was not present in the intracellular solutions used in most other studies cited above. We also included 10 mM EDTA in our extracellular solution to chelate contaminating Zn 2þ , which inhibits GluN1/2A receptors (Paoletti et al., 1997) . Our fast perfusion system was capable of rapid solution exchange (see Materials and Methods), which should not be rate-limiting for components with time constants slower thañ 0.15 s. Probably resulting from our use of high P open conditions and a relatively rapid perfusion system, our t fast values for recovery from memantine inhibition were~5-to 20-fold faster than previously reported values (Bresink et al., 1996; Gilling et al., 2007 Gilling et al., , 2009 . Thus, we hypothesize that we observed especially strong concentration dependence of recovery from memantine inhibition because our conditions encouraged fast recovery from memantine inhibition at the deep site, which is the dominant binding site at low memantine concentrations. Nevertheless, our measured t fast values probably were limited by the speed of solution exchange, especially at higher drug concentrations (see Materials and Methods), a conclusion supported by the slightly faster t 0 s recorded using outside-out patches (Parsons et al., 2008a) . The identity and concentration of intracellular permeant cations affect the voltage dependence, microscopic binding rate, and potency, but not the microscopic unbinding rate, of NMDAR channel blockers including Mg 2þ (Antonov and Johnson, 1999; Ruppersberg et al., 1994) , memantine (Chen and Lipton, 1997; Parsons et al., 1999) , and ketamine (MacDonald et al., 1991) . Since recovery from inhibition depends upon the microscopic unbinding rate of the channel blocker and the NMDAR P open , we do not expect our use of non-physiological intracellular Cs þ strongly impacted measurements of recovery from inhibition by memantine or ketamine. However, it is possible that the identity of the intracellular cation affects the development or voltage dependence of SSI. It will be important in future studies to determine how physiological intracellular K þ , which speeds the microscopic binding rates of NMDAR channel blockers compared to Cs þ , affects SSI.
The time course of recovery from inhibition by memantine was adequately fit by double exponential functions, which we used to characterize phenomenologically the speed of recovery from inhibition. However, recovery from inhibition is expected to contain many kinetic components, most of which cannot be resolved by exponential fits of whole-cell data. We determined that at least two separable processes were involved in recovery from memantine inhibition: recovery from deep site inhibition and recovery from SSI. Both processes should exhibit multiple kinetic components. The time course of the more rapid process, recovery from deep site inhibition, in principle depends on the kinetics of all channel gating transitions. However, because open channel blockers like memantine can unbind only when the channel is open, the P open of blocked channels is of primary importance. The P open of a blocked channel depends both on its intrinsic gating properties, and on any modifications of gating properties that result from channel occupation by the blocker. The NMDAR subtype dependence of maximal P open is probably the predominant determinant of the strong NMDAR subtype dependence of the time course of recovery from inhibition observed for both memantine and ketamine. Channel occupation by a blocker can result in either an increase or a decrease in the P open of blocked channels compared to the P open of unblocked channels. In the extreme case of a sequential (or foot-inthe-door) blocker, the blocker prevents channel closure (see, e.g., Antonov and Johnson, 1996; Benveniste and Mayer, 1995; Costa and Albuquerque, 1994; Koshelev and Khodorov, 1995; Paganelli and Popescu, 2015; Sobolevsky, 1999; Sobolevsky et al., 1999; Vorobjev and Sharonova, 1994) . Memantine and ketamine, in contrast, are trapping channel blockers, which permit channel closure while blocking the channel. Channel occupation by trapping channel blockers nevertheless can affect channel gating (e.g., Blanpied et al., 1997; Blanpied et al., 2005; Dilmore and Johnson, 1998; Glasgow et al., 2017; Sobolevskii and Khodorov, 2002; Sobolevsky, 1999; Sobolevsky et al., 1999) . Thus, the complex time course of recovery from inhibition at the deep site depends both on the intrinsic gating properties of the NMDAR subtype under study, and on the specific effects of a blocker on channel gating.
We identified recovery from SSI as the slower process involved in recovery from memantine inhibition based on multiple lines of evidence: (1) recovery from inhibition by memantine but not ketamine became slower at higher drug concentrations close to the memantine SSI IC 50 , and memantine but not ketamine exhibits SSI; (2) the effect of Mg 2þ on the time course of recovery from memantine inhibition and on memantine SSI exhibited the same NMDAR subtype dependence; (3) the slow component of recovery from memantine inhibition became more prominent at the higher memantine concentrations required to induce SSI; (4) the directlymeasured t recovery SSI was nearly identical to the t slow of recovery from inhibition by 100 mM memantine for both GluN1/2A and GluN1/2C receptors. Because SSI involves transit of memantine from the second site to the deep site, recovery from SSI is also likely to exhibit a complex time course of recovery. Importantly, association of memantine with the second site does not require NMDAR activation (Fig. 5) . Thus, models of NMDAR inhibition by memantine in which memantine access to both of two sites requires channel activation Sobolevsky, 1999) are inconsistent with the data presented here.
Mg 2þ accelerates recovery from memantine and ketamine inhibition via multiple mechanisms
We found that extracellular Mg 2þ accelerated recovery from memantine and ketamine inhibition, but with distinct NMDAR subtype dependence ( Fig. 3D; Fig. 4D ). Mg 2þ accelerated recovery from ketamine inhibition only from GluN1/2B receptors, which also exhibit Mg 2þ -induced potentiation via an increase in P open (Paoletti et al., 1995 (Berretta and Jones, 1996; Bouvier et al., 2015; Rodríguez-Moreno and Paulsen, 2008) as well as the extracellular solution, suggesting that, like memantine, MK-801 may be able to inhibit via multiple sites or routes. Unlike MK-801, intracellular memantine was found not to inhibit NMDARs (Parsons et al., 2008b) . However, intracellular memantine was tested only at 30 mM, a concentration much lower than the intracellular MK-801 concentration typically used to inhibit NMDARs. The ability of Mg 2þ to induce phenomenologically similar effects on the time course of recovery from inhibition by two channel blockers suggests that multiple mechanisms of inhibition may be common among NMDAR channel blockers.
Mechanism of memantine second site inhibition
In previous studies, two experimental observations were ascribed to the ability of memantine to associate with two sites: (1) the time course of recovery from memantine inhibition depended on the concentration of memantine used to inhibit the NMDAR response; (2) exposure to memantine in the absence of agonist resulted in inhibition of a subsequent NMDAR response activated by agonist application shortly after removal of memantine (Blanpied et al., 1997; Chen and Lipton, 2005; . Our data support the hypothesis that memantine's ability to associate with two sites results in concentration dependence of recovery from memantine inhibition. The memantine IC 50 is lower at the deep site than the second site, but recovery from memantine inhibition is faster from the deep site than the second site; increasing memantine concentration therefore increases association with the second site and slows recovery from inhibition. We found in addition that Mg 2þ accelerates recovery from memantine inhibition and reduces memantine SSI in an NMDAR subtypedependent manner. Both phenomena result from competition between Mg 2þ and memantine, although surprisingly, not competition for association with the second site. Instead, competition between Mg 2þ and memantine for binding to the deep site interferes with transit of memantine from the second site to the deep site. These phenomena can be explained by the hypothesis that memantine can associate with, but does not cause inhibition at, the second site; inhibition from the second site requires memantine transit to the deep site. Since memantine can associate with the second site of unactivated NMDARs, but deep site access requires channel opening, transit from the second site to the deep site likely requires channel opening. If second site to deep site transit is slow enough, it may be possible to observe development of inhibition as memantine transit takes place. We propose that the initial phase of SSI development that was particularly clear with GluN1/2C receptors (e.g., Fig. 5B and D, right; initial period of decreasing I SSI / I control ) may represent the transit of memantine from the second site to the deep site. Numerous NMDAR channel blocking antagonists other than memantine have been found to exhibit two distinct binding sites or modes, including: ketamine (Orser et al., 1997) ; some derivatives of adamantane (Antonov and Johnson, 1996) ; tetraethylammonium, MRZ 2/178, and 9-aminoacridine (Sobolevsky, 1999; Sobolevsky et al., 1999) ; amantadine and some derivatives of phencylcyclohexyl derivatives (Bolshakov et al., 2003) ; bupivacaine (Paganelli and Popescu, 2015) . However, in each of these studies, the drug was found to inhibit NMDARs when occupying either of the two sites, suggesting mechanisms of action that differ from SSI by memantine.
Where might the second site be located? Our data are not inconsistent with the hypothesis that the second site is located near the external entrance to the NMDAR channel, as previously proposed (Blanpied et al., 1997; Chen and Lipton, 2005; . However, the paradoxical combination of high IC 50 with very slow recovery from SSI suggests the second site may not be a traditional receptor binding site. An alternative possibility is that the second site represents a pool or reservoir of memantine that builds up during memantine application in the absence of agonists, and slowly depletes after memantine washout. Memantine SSI then would occur when memantine transits from the second site reservoir to the deep site. Due to memantine's lipophilicity (Chew et al., 2008; del Rio-Sancho et al., 2012; Zambrano et al., 2018) , plausible locations of a memantine second site reservoir include the intracellular compartment or the membrane (Blanpied et al., 1997) . As discussed above, there is evidence that memantine does not inhibit from the intracellular compartment (Parsons et al., 2008b) . However, the intracellular memantine concentration may reach much higher levels during the SSI protocol than the concentration previously tested. Determination of the location and the nature of the second site will require further investigation.
Full understanding of the complex effects of Mg 2þ and of SSI on properties of memantine inhibition of NMDARs also will require further investigation. For example, the therapeutic potential of targeting the second site remains to be determined. Although the memantine SSI IC 50 is much higher than the estimated memantine concentration in the brain at therapeutic doses (0.5e1 mM ), SSI is an indirect measure of memantine association with a second site. Due to these necessarily indirect measurements, there may be yet undiscovered additional consequences of memantine association with a second site at lower concentrations. For example, there could be a rapid component of memantine dissociation from the second site that we did not observe because of the 1-s wash following memantine application in our SSI protocol. If this is the case, memantine may associate with the second site at concentrations lower than those used here. Thus, it will be important to further evaluate the implications of SSI. In addition to the influence of Mg 2þ on SSI, physiological concentrations of Mg 2þ impart selectivity of memantine or ketamine for GluN2C-and GluN2D-containing NMDARs that may be of high clinical significance (Khlestova et al., 2016; Povysheva and Johnson, 2016) . Our demonstration that Mg 2þ accelerates recovery of GluN1/2A and GluN1/2B receptors from memantine inhibition, and GluN1/2B receptors from ketamine inhibition, reveals that Mg 2þ has NMDAR subtype-selective effects on drug kinetics as well as on IC 50 . Insights into NMDAR inhibition by memantine and ketamine, in addition to advancing knowledge of two clinically useful drugs, may help elucidate broad mechanisms of NMDAR inhibition.
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